My Home About Me

by Hisham S. Ayoub, DMD
BioHealth Investor



Shares of Corcept Therapeutics, Inc. (CORT) continued their strong upward movement on Monday gaining more than 20% by day's end.


The stock has now gained more than 70% in three days since the company announced positive results from its preclinical investigation of weight loss through the combination of olanzapine plus CORLUX.

This prompted Punk, Ziegel & Co. to raise its outlook on Corcept stock from "market perform" to "accumulate".

What was really impressive about this three day rally is how strong the volume has been, signalling that large institutional investors might be involved. Volume over the last three days, Thursday, Friday and Monday, was 538,400 / 891,300 / 822,967 respectively, while the 3-month daily average volume is a little over 70,000 according to Yahoo!Finance.

This wild action in Corcept stock can be attributed to two things; the relatively tiny market cap of just $90 million, and of course, the fascination of the world with image and weight loss.

Investors must be careful here however, there still is a long way to go before Corcept's weight loss program adds anything to its bottom line.



RELATED READING:
- Sanofi Should Blame Itself for FDA Panel's Rejection of Acomplia




Dr.Ayoub is the founding editor of BioHealth Investor
________________

bailout   Basic Materials SPDR (XLB)   bond trading   bond yields   capitulation   climactic   commodities   credit crisis   Currency ETFs   day trading   Deron Wagner   DJIA chart   economic data   Emini's Nas 100   emini's S&P 500   emini's S&P 500e   ETFs (exchange trade funds)   ETFs (exchange traded funds)   Gold Miners ETF (GDX)   Japanese Yen ETF (FXY)